Over 10 North Carolina Auctions End Today - Bid Now
Over 150 Total Lots Up For Auction at Three Locations - Over 40 Ohio Auctions End Tomorrow 03/06 - Bid Now, CA 03/08, CA 03/15

FDA clears Qure.ai's qXR-CTR chest X-ray solution as a potential indicator for identifying heart failure risk

Press releases may be edited for formatting or style | September 29, 2023 Artificial Intelligence Cardiology X-Ray
New York, 29 September 2023: Qure.ai, a leading global innovator in radiology AI solutions, has announced FDA clearance for measuring the cardiothoracic ratio (CTR) utilizing its artificial intelligence-enabled chest X-ray solution, qXR-CTR. This remarkable achievement marks another significant milestone for the organization, solidifying its position as a trailblazer in AI-driven medical imaging innovation.

The qXR-CTR is a deep-learning-based computer vision algorithm designed for use by physicians in all inpatient and outpatient settings, to automate the CTR assessment on chest radiographs (CXR). Precisely, it measures the ratio of the maximum transverse diameter of the heart to the maximum inner transverse diameter of the thoracic cavity, providing the most accurate indicator of cardiomegaly on plain film. This cutting-edge technology leverages artificial intelligence algorithms to deliver precise and efficient results, saving time for physicians and improving diagnostic accuracy.

Prashant Warier, Co-Founder and CEO at Qure.ai, said, "We are delighted to receive FDA clearance for qXR-CTR. This cutting-edge algorithm enhances the accuracy and efficiency of CTR assessment and empowers healthcare professionals with a valuable tool to diagnose and monitor risk of heart failure. This achievement reaches an industry record for the greatest number of FDA-cleared findings on CXR scans, demonstrating Qure.ai's commitment to advancing better patient outcomes through AI-driven solutions."
DOTmed text ad

Reveal Mobi Pro now available for sale in the US

Reveal Mobi Pro integrates the Reveal 35C detector with SpectralDR technology into a modern mobile X-ray solution. Mobi Pro allows for simultaneous acquisition of conventional & dual-energy images with a single exposure. Contact us for a demo at no cost.

The clearance of qXR-CTR marks the company's 12th FDA-cleared algorithm, solidifying its position as an industry leader. Previous FDA-cleared findings by Qure.ai include Endotracheal Tube location, Tracheostomy tube location, Pneumothorax, and Pleural Effusion identification for CXR; qER for intracranial haemorrhage detection on head CT scans, and qER Quant for quantifying critical abnormalities on head CT scans.

Heart failure is a complex, life-threatening cardiac condition often misdiagnosed due to its nonspecific symptoms. With qXR-CTR now being cleared by the FDA, Qure's chest X-ray algorithm can be deployed to jointly screen for increased cardiothoracic ratio (CTR) and Pleural effusion along with other radiographic markers associated with the presence of heart failure. This remarkable achievement is a significant advancement for medical imaging and cardiac care, opening new avenues for the early detection of heart failure through automated assessment of chest radiographs.

You Must Be Logged In To Post A Comment